1. Home
  2. ENVX vs IOVA Comparison

ENVX vs IOVA Comparison

Compare ENVX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$4.96

Market Cap

1.3B

Sector

Miscellaneous

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
IOVA
Founded
2006
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
ENVX
IOVA
Price
$4.96
$3.42
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$13.61
$9.11
AVG Volume (30 Days)
5.1M
15.2M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
40.94
14.84
EPS
N/A
N/A
Revenue
$31,821,000.00
N/A
Revenue This Year
$38.76
$51.55
Revenue Next Year
$218.24
$37.55
P/E Ratio
N/A
N/A
Revenue Growth
37.91
N/A
52 Week Low
$4.67
$1.64
52 Week High
$16.49
$5.63

Technical Indicators

Market Signals
Indicator
ENVX
IOVA
Relative Strength Index (RSI) 43.33 44.19
Support Level $4.69 $2.02
Resistance Level $5.56 $4.34
Average True Range (ATR) 0.31 0.27
MACD 0.07 -0.12
Stochastic Oscillator 31.58 17.89

Price Performance

Historical Comparison
ENVX
IOVA

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: